Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

Aberrant activation in fibroblast growth factor signaling has been implicated in the development of various cancers, including squamous cell lung cancer, squamous cell head and neck carcinoma, colorectal and bladder cancer. Thus, fibroblast growth factor receptors (FGFRs) present promising targets f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cancer
Main Authors: Grünewald, Sylvia, Politz, Oliver, Bender, Sebastian, Héroult, Mélanie, Lustig, Klemens, Thuss, Uwe, Kneip, Christoph, Kopitz, Charlotte, Zopf, Dieter, Collin, Marie‐Pierre, Boemer, Ulf, Ince, Stuart, Ellinghaus, Peter, Mumberg, Dominik, Hess‐Stumpp, Holger, Ziegelbauer, Karl
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Cancer Therapy and Prevention
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6766871/
https://ncbi.nlm.nih.gov/pubmed/30807645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32224
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados